Skip to main content
iNtRON Biotechnology, Inc. logo

iNtRON Biotechnology, Inc. — Investor Relations & Filings

Ticker · 048530 ISIN · KR7048530000 KO Manufacturing
Open in API
Filings indexed 268 across all filing types
Latest filing 2021-03-17 Audit Report / Informat…
Country KR South Korea
Listing KO 048530

About iNtRON Biotechnology, Inc.

https://intronbio.com:6001

iNtRON Biotechnology, Inc. is a biotechnology company specializing in solutions for infectious diseases. Its core activities are centered on three main pillars: bio-new drugs, molecular diagnostics, and molecular biology reagents. The company's therapeutic pipeline focuses on developing novel treatments for drug-resistant super-bacteria, creating antibiotic alternatives and other bio-active agents to address the challenge of antimicrobial resistance (AMR). In its diagnostics division, iNtRON develops and manufactures detection kits and assays, primarily based on real-time PCR technology, for the rapid identification of infectious organisms. The company also provides a range of molecular reagents for research and has commercialized antibiotic alternative products for the animal health market.

Recent filings

Filing Released Lang Actions
사업보고서 (2020.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive financial report titled '감사보고서' (Audit Report) for Intron Biotechnology, covering the fiscal year 2020. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. While it contains an audit report, the inclusion of the full set of financial statements and notes for the fiscal year classifies it as an Annual Report (10-K equivalent in the context of Korean corporate filings). FY 2020
2021-03-17 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (often associated with the DART system) used to solicit shareholder votes for an upcoming Annual General Meeting (AGM). While it contains financial statements, these are provided as supporting information for the meeting agenda rather than being the primary Annual Report (10-K). Therefore, it is classified as Proxy Solicitation & Information Statement.
2021-03-10 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Intron Biotechnology. It contains the meeting agenda, details on voting procedures (including electronic voting), and management information regarding business operations and strategy. This type of document is standard for providing shareholders with the necessary information to vote on board appointments, financial statements, and other corporate matters, which falls under the Proxy Solicitation & Information Statement category.
2021-03-10 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system (KIND) regarding a significant change in financial results (30% or more change in revenue or profit structure). It provides preliminary financial data, including revenue, operating profit, and net income, and explicitly states that these figures are pre-audit. This type of disclosure is a standard regulatory requirement for listed companies to announce significant financial shifts before the final annual report is published. It fits the 'Earnings Release' (ER) category as it provides key financial highlights and the reasons for the performance change. FY 2020
2021-02-24 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of an upcoming Annual General Meeting (AGM) for Intron Biotechnology. It details the date, location, agenda items (such as financial statement approval, director appointments, and remuneration limits), and information regarding electronic voting. This document serves as the official solicitation and notification to shareholders regarding the meeting, which falls under the Proxy Solicitation & Information Statement category.
2021-02-05 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details the changes in share ownership by Quad Investment Management Corp. in Intron Biotechnology. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership thresholds and changes.
2021-02-04 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.